Jefferies Financial Group Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a research note issued on Friday, Marketbeat Ratings reports. They presently have a £180 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 17.89% from the stock’s previous close.

Several other equities analysts have also recently issued reports on AZN. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a research note on Thursday, January 15th. Citigroup increased their target price on shares of AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday. Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Finally, Berenberg Bank increased their price objective on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a report on Tuesday, January 27th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of £152.50.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at £152.69 on Friday. The stock has a market cap of £236.79 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 0.86 and a beta of 0.28. The firm’s 50-day moving average is £146.93 and its 200 day moving average is £137.50. AstraZeneca has a 1 year low of GBX 9,651 and a 1 year high of £157.32. The company has a debt-to-equity ratio of 60.87, a current ratio of 0.94 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.